RxDoctor Payments Data

David Zehr

Nurse Practitioner · French Lick, INNPI 1518070929

Payments from drug & device makers

$2,002in general payments, 2019–2025

Across 116 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$396
  • Novartis$283
  • AstraZeneca$245
  • Bayer$176
  • Lilly USA, LLC$123
  • Biohaven Pharmaceutical Holding Company Ltd.$108
  • plus $671 from 16 others

What the payments were for

  • Food & beverage$1,97899%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,002 in reported general payments places this provider in the 80th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$1,596
Medicare patients
50
Services billed
93

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$121,548
OzempicSemaglutide48$77,848
JardianceEmpagliflozin74$49,812
FarxigaDapagliflozin Propanediol51$44,735
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$41,112
TrulicityDulaglutide23$28,747
Tresiba Flextouch U-200Insulin Degludec22$27,415
MounjaroTirzepatide17$26,385
TradjentaLinagliptin32$24,868
RybelsusSemaglutide17$18,493
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog33$13,830
XareltoRivaroxaban14$13,412
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$13,165
Fiasp FlextouchInsulin Aspart (Niacinamide)16$12,309
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$11,069

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$396$96,34165 claims
Boehringer IngelheimJardiance, Tradjenta$78$74,680106 claims
AstraZenecaFarxiga, Breztri Aerosphere$245$57,90167 claims
Lilly USA, LLCTrulicity, Mounjaro$123$55,13140 claims
GSKTrelegy Ellipta, Breo Ellipta$52$49,97765 claims
AbbVieSynthroid$105$6,20275 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in French Lick

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →